{
  "trial_id": "NCT02175212",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, Gleason Score, PSA level, Tumor Stage, Karnofsky Performance Status, Prior treatments, Participating institution, Ethnicity, Body Mass Index (BMI), Smoking status, Comorbidities, Family history of prostate cancer, Medication use, Baseline testosterone levels, Baseline hemoglobin levels.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Gleason score (categorical)",
          "Gleason Score"
        ],
        [
          "PSA (continous)",
          "PSA level"
        ],
        [
          "T stage (categorical)",
          "Tumor Stage"
        ],
        [
          "Karnofsky Index (KI) performance status \u226570%",
          "Karnofsky Performance Status"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Male",
        "Risk subgroup (intermediate vs. high)",
        "PSA (categorical)",
        "Positive biopsy samples (continous)",
        "Prostate radiotherapy dose (continous)",
        "Prostate radiotherapy dose (categorical)",
        "Pelvic radiotherapy (categorical)"
      ],
      "remaining_candidate_features": [
        "Prior treatments",
        "Participating institution",
        "Ethnicity",
        "Body Mass Index (BMI)",
        "Smoking status",
        "Comorbidities",
        "Family history of prostate cancer",
        "Medication use",
        "Baseline testosterone levels",
        "Baseline hemoglobin levels"
      ]
    },
    "processed-gen-response": "Age, Gleason Score, PSA level, Tumor Stage, Karnofsky Performance Status, Prior treatments, Participating institution, Ethnicity, Body Mass Index (BMI), Smoking status, Comorbidities, Family history of prostate cancer, Medication use, Baseline testosterone levels, Baseline hemoglobin levels."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, Prostate-Specific Antigen (PSA) levels, Gleason Score, Tumor Stage, Karnofsky Performance Status,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "Risk subgroup (intermediate vs. high)",
          "Tumor Stage"
        ],
        [
          "PSA (continous)",
          "Prostate-Specific Antigen (PSA) levels"
        ],
        [
          "Gleason score (categorical)",
          "Gleason Score"
        ],
        [
          "Karnofsky Index (KI) performance status \u226570%",
          "Karnofsky Performance Status"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "T stage (categorical)",
        "PSA (categorical)",
        "Positive biopsy samples (continous)",
        "Prostate radiotherapy dose (continous)",
        "Prostate radiotherapy dose (categorical)",
        "Pelvic radiotherapy (categorical)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment"
      ]
    },
    "processed-gen-response": "Age, Sex: Male, Race/Ethnicity, Region of Enrollment, Prostate-Specific Antigen (PSA) levels, Gleason Score, Tumor Stage, Karnofsky Performance Status"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Karnofsky Index, Prostatic Specific Antigen, Gleason Score, Tumor Stage, Body Mass Index, Region of Enrollment, Previous Prostate Cancer Treatment, Family History of Prostate Cancer,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "Risk subgroup (intermediate vs. high)",
          "Tumor Stage"
        ],
        [
          "PSA (continous)",
          "Prostatic Specific Antigen"
        ],
        [
          "Gleason score (categorical)",
          "Gleason Score"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "T stage (categorical)",
        "PSA (categorical)",
        "Positive biopsy samples (continous)",
        "Prostate radiotherapy dose (continous)",
        "Prostate radiotherapy dose (categorical)",
        "Pelvic radiotherapy (categorical)"
      ],
      "remaining_candidate_features": [
        "Karnofsky Index",
        "Body Mass Index",
        "Region of Enrollment",
        "Previous Prostate Cancer Treatment",
        "Family History of Prostate Cancer"
      ]
    },
    "processed-gen-response": "Age, Sex: Male, Karnofsky Index, Prostatic Specific Antigen, Gleason Score, Tumor Stage, Body Mass Index, Region of Enrollment, Previous Prostate Cancer Treatment, Family History of Prostate Cancer"
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, race, Karnofsky Index (KI) performance status, Gleason Score, Prostatic Specific Antigen (PSA) level, tumor stage (cT1c-3b), nodal status (N0), metastatic status (M0), histological grade, body mass index (BMI), medical history (e.g., previous surgical treatment, pelvic radiotherapy, concomitant use of chemotherapy), smoking status, family history of prostate cancer.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Risk subgroup (intermediate vs. high)",
          "tumor stage (cT1c-3b)"
        ],
        [
          "T stage (categorical)",
          "tumor stage (cT1c-3b)"
        ],
        [
          "PSA (continous)",
          "Prostatic Specific Antigen (PSA) level"
        ],
        [
          "Gleason score (categorical)",
          "Gleason Score"
        ],
        [
          "Karnofsky Index (KI) performance status",
          "Karnofsky Index (KI) performance status"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Male",
        "PSA (categorical)",
        "Positive biopsy samples (continous)",
        "Prostate radiotherapy dose (continous)",
        "Prostate radiotherapy dose (categorical)",
        "Pelvic radiotherapy (categorical)"
      ],
      "remaining_candidate_features": [
        "race",
        "nodal status (N0)",
        "metastatic status (M0)",
        "histological grade",
        "body mass index (BMI)",
        "medical history (e.g., previous surgical treatment, pelvic radiotherapy, concomitant use of chemotherapy)",
        "smoking status",
        "family history of prostate cancer."
      ]
    },
    "processed-gen-response": "Age, race, Karnofsky Index (KI) performance status, Gleason Score, Prostatic Specific Antigen (PSA) level, tumor stage (cT1c-3b), nodal status (N0), metastatic status (M0), histological grade, body mass index (BMI), medical history (e.g., previous surgical treatment, pelvic radiotherapy, concomitant use of chemotherapy), smoking status, family history of prostate cancer."
  }
}